Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Structure Therapeutics, Inc. Sponsored ADR (GPCR)
NASDAQ:GPCR
RESEARCH TOOLSreports
Structure Therapeutics, Inc. Sponsored ADR (GPCR) Stock Price & Analysis
154 Followers
GPCR Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$21.79 - $75.02
Previous Close$36.07
Volume495.80K
Average Volume (3M)593.28K
Market Cap
$1.68B
Enterprise Value$1.22B
Total Cash (Recent Filing)$467.32M
Total Debt (Recent Filing)$5.45M
Price to Earnings (P/E)-15.6
Beta0.98
Next Earnings
Aug 08, 2024EPS Estimate
-$0.23Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.31
Shares Outstanding46,621,123
10 Day Avg. Volume472,935
30 Day Avg. Volume593,284
Standard Deviation0.30
R-Squared0.25
Alpha0.13
Financial Highlights & Ratios
Price to Book (P/B)3.87
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-12.20
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-13.69
Forecast
1Y Price Target
$78.83Price Target Upside119.70% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
Structure Therapeutics, Inc. Sponsored ADR News
Bulls Say, Bears Say
Bulls Say
Drug Development PipelinePlanned initiation of a Ph2b nondiabetic obesity study later this year with data disclosure expected the following year, showing a clear development pipeline.
Financial HealthA robust cash position with $436.4M expected to fund operations through at least 2026, demonstrating strong financial health.
Market PositioningAnalyst's Outperform rating is grounded on the differentiation and potential of Structure's oral GLP-1 products in a market seeking more accessible and affordable options.
Bears Say
Competitive PositionConcerns remain as Novo's oral amycretin details are scarce and the clinical program is undefined.
Drug EfficacyIf the 12-week weight loss results do not approach competitor orforglipron's performance without liver toxicity concerns, it may negatively impact the stock.
Financial HealthThe company has an annualized cash burn of $224 million with roughly two years of cash left, indicating a need to manage financial resources or seek additional funding.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
GPCR FAQ
What was Structure Therapeutics, Inc. Sponsored ADR’s price range in the past 12 months?
Structure Therapeutics, Inc. Sponsored ADR lowest stock price was $21.79 and its highest was $75.02 in the past 12 months.
What is Structure Therapeutics, Inc. Sponsored ADR’s market cap?
Currently, no data Available
When is Structure Therapeutics, Inc. Sponsored ADR’s upcoming earnings report date?
Structure Therapeutics, Inc. Sponsored ADR’s upcoming earnings report date is Aug 08, 2024 which is in 83 days.
How were Structure Therapeutics, Inc. Sponsored ADR’s earnings last quarter?
Structure Therapeutics, Inc. Sponsored ADR released its earnings results on May 09, 2024. The company reported -$0.19 earnings per share for the quarter, beating the consensus estimate of -$0.194 by $0.004.
Is Structure Therapeutics, Inc. Sponsored ADR overvalued?
According to Wall Street analysts Structure Therapeutics, Inc. Sponsored ADR’s price is currently Undervalued.
Does Structure Therapeutics, Inc. Sponsored ADR pay dividends?
Structure Therapeutics, Inc. Sponsored ADR does not currently pay dividends.
What is Structure Therapeutics, Inc. Sponsored ADR’s EPS estimate?
Structure Therapeutics, Inc. Sponsored ADR’s EPS estimate is -$0.23.
How many shares outstanding does Structure Therapeutics, Inc. Sponsored ADR have?
Structure Therapeutics, Inc. Sponsored ADR has 46,598,040 shares outstanding.
What happened to Structure Therapeutics, Inc. Sponsored ADR’s price movement after its last earnings report?
Structure Therapeutics, Inc. Sponsored ADR reported an EPS of -$0.19 in its last earnings report, beating expectations of -$0.194. Following the earnings report the stock price went down -7.322%.
Which hedge fund is a major shareholder of Structure Therapeutics, Inc. Sponsored ADR?
Among the largest hedge funds holding Structure Therapeutics, Inc. Sponsored ADR’s share is Driehaus Capital Management LLC. It holds Structure Therapeutics, Inc. Sponsored ADR’s shares valued at 106M.
---
Structure Therapeutics, Inc. Sponsored ADR Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$78.83 (119.70% Upside)
$78.83 (119.70% Upside)
Blogger Sentiment
Bullish
GPCR Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 866.7K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.2%
Last 30 Days ▼ 3.3%
Last 30 Days ▼ 3.3%
Technicals
SMA
Negative
20 days / 200 days
Momentum
38.73%
12-Months-Change
Fundamentals
Return on Equity
-29.29%
Trailing 12-Months
Asset Growth
84.85%
Trailing 12-Months
Company Description
Structure Therapeutics, Inc. Sponsored ADR
Structure Therapeutics Inc is a clinical stage global biopharmaceutical company aiming to develop and deliver novel oral therapeutics to treat a wide range of chronic diseases with unmet medical need.
---
GPCR Stock 12 Month Forecast
Average Price Target
$78.83
▲(119.70% Upside)
Technical Analysis
Best Analysts Covering GPCR
1 Year
1 Year Success Rate
4/6 ratings generated profit
1 Year Average Return
+8.10%
initiated a buy rating 7 days ago
Copying Evan Seigerman's trades and holding each position for 1 Year would result in 66.67% of your transactions generating a profit, with an average return of +8.10% per trade.
---